Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, Lin SH, Wistuba II, Agarwal R, Blazar M, Mehta DR, Al Baghdadi T, Jin N, Massa RC, Hamilton SR, Staley CA, Wong TZ, O’Dwyer PJ A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174) , J Clin Oncol: 2024
Lee H, Kipnis S, O’Brien S, Eads JR, Katona BW, Pryma DA Real-world 177Lu-DOTATATE peptide receptor radionucleotide therapy: treatment outcomes with dosing variations an in non-midgut neuroendocrine tumors , ASCO GI Symposium: 2024
Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge JE, Myers G, Wang Y, Zhao X, Tomchuck S, Dubyak G, Lee RT, Estfan B, Shapiro M, Kamath S, Mohamed A, Huang SC, Huang AY, Conlon R, Krishnamurthi S, Eads J, Willis JE, Khorana AA, Bajor D, Wang Z Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer , J Clin Invest: 2024
Chapin WJ, Massa R, Eads JR Defining the role of neoadjuvant therapy for gastroesophageal cancers , Advances in Oncology: 2024
Soulen MC, Teitelbaum UR, Mick R, Eads J, Mondschein JL, Dagli M, van Houten D, Damjanov N, Schneider C, Cengel K, Metz DC Integrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study , Cardiovasc Intervent Radiol: 2024
Alese OB, Wu C, Chapin WJ, Ulanja MB, Zheng-Lin B, Amankwah M, Eads JR Update on emerging therapies for advanced colorectal cancer , Am Soc Clin Oncol Edu Book: 2023
Karasic TB, Eads JR, Goyal L Precision medicine and immunotherapy have arrived for cholangiocarcinoma: an overview of recent approvals and ongoing trials , JCO Precision Oncology: 2023
Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms , Endocr Relat Cancer: 2023
Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, De. Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting , J Natl Cancer Inst: 2023
Lee H, Kipnis ST, Niman R, O'Brien SR, Eads JR, Katona BW, Prymna DA Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT , Cancers (Basel): 2023
